International generic name Cinnarizine
Drug form and composition Tablets. One tablet contains 25 mg Cinnarizine.
Indications Labyrinthopaty, vascular vestibulopathy, Meniere’s disease; prevention and treatment of kinesis.
Dosage and administration Cinnarizin is used orally, before nutrition. In prevention of kinesis - 25 mg, a half to one hour before the traveling, and after that - 25 mg each 6 hours. For the treatment of patients with labyrinthopaty, vestibular disorders, and Meniere’s disease the dose is 75 mg, given three times daily. Maximal dose in adults is 225 mg/24 h. In order to achieve an optimal therapeutic effect Cinnarizin should be used for several months. In elderly patients the treatment should be started with low doses (average ½ of the recommended dose), with gradually increase of the daily dose until the expected therapeutic effect is achieved. In children recommended daily dose is average ¼ of the daily dose in adults.
Contraindications Hypersensitivity to the preparation; pregnancy and lactation.
Special warnings and precautions The preparation should be used with care in: adult patients, children, patients with family history or clinical manifestations of extrapyramidal disorders. In persons with hypotension during the treatment the blood pressure should be monitored. In long-term treatment with Cinnarizin hematology variables, liver and renal laboratory tests should be monitored. Cinnarizin may cause a somnolence, which reduces the attention and disturbs the driving capabilities, particularly in the beginning of the treatment. This requires special care when using the medicine in drivers and machinery operating persons.
Drug interactions Cinnarizine may potentiate the effects of the antidepressants and alcohol. Antiacide medicines and H2-blockers accelerate the resorption of the preparation, reducing acidity of the stomach fluid. Nootrope agents and vasodilators increase Cinnarizin effects.
Adverse reactions At the onset of the treatment the most frequent adverse reactions are: somnolence, abdominal pain and discomfort, which usually are transitory and resolve after the dose adjustment. Hypersensitivity reactions usually affect the skin. Cinnarizin may intensify the trend to hypotension reactions or preexistent hypotension, xerostomia, appetite increase. The most serious adverse reactions are extrapyramidal disorders (tremor, disorientation, balance disorders), including Parkinson’s syndrome. Cinnarizin may cause false doping-positive reactions in sportsmen. Due to its antihistamine effect Cinnarizin may lead to false - negative result in intradermal hypersensitivity testing. In this reason the treatment with the preparation should be discontinued at least 4 days before the testing.
Pharmacological mechanisms Cinnarizin improves the brain and peripheral microcirculation, antagonizing vascular effects of the endogenous monoamines and oligopeptides, and blocking the calcium influx in the myocytes of the vessel wall. The preparation possesses a high affinity to the vessel smooth muscle cells in the brain. It reduces the erythrocyte deformity and improves rheology of the blood. Improves the cell resistance to hypoxia. Cinnarizin has no cardiodepressive effect. Reduces nystagmus and other vestibular disorders, reduces the labyrinth irritability. Exerts certain antihystamine action.
Supplied 50 tablets of 25 mg.
Expiry 3 years. |